Therapixel, the AI company winner of the DREAM Digital Mammography challenge, has secured EUR5 million in Series A financing, with Omnes and M Capital Partners joining its existing pool of investors.
Sacha Loiseau, Chairman and Founder of Mauna Kea Technologies, has been appointed as independent Board Member and subsequently elected Chairman of the Board. Maximilien Fournier-Sourdille, an associate at Omnes and an experienced MedTech executive and investor, also joins the Board of Director, along with Yoann Bonnamour from M Capital Partners.
Olivier Clatz, co-founder of Therapixel, has recently been named by the French Innovation Council as ‘AI for diagnosis’ Program Manager; he will smoothly transition out of the Company. Pierre Fillard, CTO and co-founder, has been appointed CEO until a new chief executive joins the Company.
Pierre Fillard, co-founder and CEO of Therapixel, declared: “Therapixel is entering a new and exciting phase. With this financing round and the strengthening of our governance, I am confident that we will continue to attract the best talents and maintain our leadership.”
Loiseau adds: “Therapixel has proven to be a leader in the field of artificial intelligence applied to one of the key challenges in cancer screening. I am delighted to join the company at this key moment and to work hand in hand with Pierre and his team to bring value to our shareholders.”
“Therapixel’s team is truly outstanding and has succeeded in demonstrating, over and over, its technical superiority”, says Fournier-Sourdille, Associate at Omnes. “We are pleased to join this journey and strongly believe Therapixel is geared to achieve a major improvement in breast cancer screening”.
Bonnamour, Senior Associate at M Capital Partners, adds: “We’re excited to support the outstanding team at Therapixel and to help tackle one of the most important challenges in healthcare today.”
